The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
The prevalence of HCV genotypes in the US is about 75% for genotype 1, 20-25% for genotypes 2 and 3, and <2% for genotypes 4, 5, and 6 combined. Genotype testing is recommended to determine the optimal treatment regimen.1
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C. JAMA. 2017;317(6):639-640. doi:10.1001/jama.2016.12279